Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 3
2021 14
2022 9
2023 7
2024 12
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Unknown field was ignored: [Grants and Funding]
Page 1
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers.
Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS. Son J, et al. Clin Cancer Res. 2024 Jul 15;30(14):2986-2995. doi: 10.1158/1078-0432.CCR-23-2819. Clin Cancer Res. 2024. PMID: 38687597
The highest prevalence of KRAS mutation was in mesonephric-like endometrial (100%, n = 9/9), mesonephric-like ovarian (83.3%, n = 5/6), mucinous ovarian (60.4%), and low-grade serous ovarian (44.4%) cancers. After adjustment for age, cancer type, and grade, RAS mutation wa …
The highest prevalence of KRAS mutation was in mesonephric-like endometrial (100%, n = 9/9), mesonephric-like ovarian (83.3%, n = 5/6), muci …
Editorial: Online Adaptive MR-Guided Radiotherapy.
Kerkmeijer LGW, Valentini V, Fuller CDD, Slotman BJ. Kerkmeijer LGW, et al. Front Oncol. 2021 Aug 30;11:748685. doi: 10.3389/fonc.2021.748685. eCollection 2021. Front Oncol. 2021. PMID: 34527596 Free PMC article. No abstract available.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. Piha-Paul SA, et al. Oncologist. 2024 Apr 4;29(4):e514-e525. doi: 10.1093/oncolo/oyad338. Oncologist. 2024. PMID: 38297981 Free PMC article. Clinical Trial.
In 43 response-evaluable patients, 13 (30.2%) achieved partial response (PR; n = 7) or stable disease (SD) 24 weeks (n = 6), including 4/11 (36.4%) with FGFR2 mutations/fusions and cholangiocarcinoma (PR n = 3; SD 24 weeks n = 1), 3/3 (100.0%) with hormone receptor (HR)-positive/ …
In 43 response-evaluable patients, 13 (30.2%) achieved partial response (PR; n = 7) or stable disease (SD) 24 weeks (n = 6), including 4/11 …
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Piha-Paul SA, et al. NPJ Precis Oncol. 2024 Jul 31;8(1):166. doi: 10.1038/s41698-024-00634-6. NPJ Precis Oncol. 2024. PMID: 39085400 Free PMC article.
Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. ...
Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. ...
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward.
Steinmetz AR, Mokkapati S, McConkey D, Dinney CP. Steinmetz AR, et al. Bladder Cancer. 2024 Jun 18;10(2):105-112. doi: 10.3233/BLC-230083. eCollection 2024. Bladder Cancer. 2024. PMID: 39131870 Free PMC article. Review.
BACKGROUND: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNalpha/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene therapy developed for bladder cancer. ...O …
BACKGROUND: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNalpha/Syn3) was FDA approved in 2022 for non-muscle invasive blad …
Development and Standardization of a Classification System for Osteoradionecrosis: Implementation of a Risk-Based Model.
Watson EE, Hueniken K, Lee J, Huang SH, Maghrabi A AE, Xu W, Moreno AC, Tsai CJ, Hahn E, McPartlin AJ, Yao CM, Goldstein DP, De Almeida JR, Waldon JN, Fuller CD, Hope AJ, Ruggiero SL, Glogauer M, Hosni AA. Watson EE, et al. medRxiv [Preprint]. 2023 Sep 13:2023.09.12.23295454. doi: 10.1101/2023.09.12.23295454. medRxiv. 2023. Update in: J Clin Oncol. 2024 Jun 1;42(16):1922-1933. doi: 10.1200/JCO.23.01951 PMID: 37745576 Free PMC article. Updated. Preprint.
The aim of this study is to identify ORN risk factors and develop a novel classification to depict the severity of ORN. METHODS: Consecutive head-and-neck cancer (HNC) patients treated with curative-intent IMRT ( 45Gy) in 2011-2018 were included. ...
The aim of this study is to identify ORN risk factors and develop a novel classification to depict the severity of ORN. METHODS: Consecutive …
Adhering to Eat and Exercise Status During Radiotherapy for Oropharyngeal Cancer for Prevention and Mitigation of Radiotherapy-Associated Dysphagia.
Barbon CEA, Peterson CB, Moreno AC, Lai SY, Reddy JP, Sahli A, Martino R, Johnson FM, Fuller CD, Hutcheson KA. Barbon CEA, et al. JAMA Otolaryngol Head Neck Surg. 2022 Oct 1;148(10):956-964. doi: 10.1001/jamaoto.2022.2313. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36074459 Free PMC article.
The current study seeks to validate the authors' previously published findings in a large contemporary cohort of patients with oropharynx cancer (OPC) and address limitations of the prior retrospective study using prospective, validated outcome measures. ...MAIN OUTCOMES A …
The current study seeks to validate the authors' previously published findings in a large contemporary cohort of patients with oropharynx …
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Vo HH, et al. NPJ Precis Oncol. 2022 Oct 27;6(1):78. doi: 10.1038/s41698-022-00317-0. NPJ Precis Oncol. 2022. PMID: 36302890 Free PMC article.
We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254). Patients with metastatic cancer underwent tumor profiling and were randomized between the two arms whe …
We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (Cli …
Inhibition of the CD47-SIRPalpha axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data.
Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Son J, et al. Front Immunol. 2022 Nov 11;13:1027235. doi: 10.3389/fimmu.2022.1027235. eCollection 2022. Front Immunol. 2022. PMID: 36439116 Free PMC article.
CD47-SIRPalpha interaction acts as a "don't eat me" signal and is exploited by cancer to downregulate innate and adaptive immune surveillance. There has been intense interest to develop a mechanism of blockade, and we aimed to analyze the emerging data from early clinical …
CD47-SIRPalpha interaction acts as a "don't eat me" signal and is exploited by cancer to downregulate innate and adaptive immune surv …
41 results